EOLS 16.54 Evolus, Inc.
| Range: | 7.44-17.7 | Vol Avg: | 551945 | Last Div: | 0 | Changes: | 0.35 |
| Beta: | 1.31 | Cap: | 1.07B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Feb 08 2018 | Empoloyees: | 304 | ||
| CUSIP: | 30052C107 | CIK: | 0001570562 | ISIN: | US30052C1071 | Country: | US |
| CEO: | Mr. David Moatazedi | Website: | https://www.evolus.com | ||||
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Stock Details
Positive 0.29
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty ...
businesswire.com·Sat Oct 12 2024
Positive 0.33
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty ...
businesswire.com·Sat Sep 28 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow